Previous 10 | Next 10 |
IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years ...
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the publication of a study evaluating tegoprubart as an immunomodulatory monotherapy in nonhuman primate kidney and islet allotransplants. The study, entitl...
IRVINE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the first participant has been dosed in the Company’s Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiv...
2023-08-23 08:47:02 ET VCI Global ( VCIG ) +61% after announces visionary collaboration with Microsoft Azure OpenAI . iTeos Therapeutics ( ITOS ) +37% in reaction as Roche send anti-TIGIT developers higher after mistakenly-released cancer drug data . Arcus ...
10 th patient dosed marks achievement of first clinical milestone associated with next tranche of funding Eledon to report updated interim clinical data from the ongoing Phase 1b trial of tegoprubart in kidney transplantation at ASN Kidney Week in November 2023 IRVINE,...
2023-08-10 12:26:46 ET Eledon Pharmaceuticals press release ( NASDAQ: ELDN ): Q2 GAAP EPS of -$0.40 beats by $0.06 . The company had approximately $71.4 million in cash and cash equivalents and short-term investments as of June 30, 2023, compared to ...
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation; updated clinical data expected in the fourth quarter Raised up to $185 million, including $35 million upfront, from leading investors Successfully completed a non-...
IRVINE, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming Jefferies Healthcare Conference on Friday, June 9, 20...
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is one of today's top gainers. The company's shares are currently up 19.43% on the day to $2.09. Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease a...
2023-05-31 13:10:47 ET Gainers: Aridis Pharmaceuticals ( ARDS ) +130% . Marker Therapeutics MRKR +31% . SunCar Technology Group SDA +27% . T Stamp ( IDAI ) +25% . Inventiva ( IVA ) +19% . Eledon Pharmaceuticals ( ELDN ) +19% ...
News, Short Squeeze, Breakout and More Instantly...
Eledon Pharmaceuticals Inc Com Company Name:
ELDN Stock Symbol:
NASDAQ Market:
Eledon Pharmaceuticals Inc Com Website:
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, ...
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m² Mean eGFR measured above 60 mL/min/1.73m...